Blader JC, Carlson GA. Increased rates of bipolar disorder diagnoses among U.S. child, adolescent, and adult inpatients, 1996–2004. Biol Psychiatry. 2007;62:107–14.
Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry. 2007;64:1032–9.
Van Meter AR, Moreira AL, Youngstrom EA. Meta-analysis of epidemiologic studies of pediatric bipolar disorder. J Clin Psychiatry. 2011;72:1250–6.
Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49:980–9.
Lofthouse N, Fristad MA. Psychosocial interventions for children with early-onset bipolar spectrum disorder. Clin Child Fam Psychol Rev. 2004;7:71–88.
Freeman AJ, Youngstrom EA, Michalak E, Siegel R, Meyers OI, Findling RL. Quality of life in pediatric bipolar disorder. Pediatrics. 2009;123:e446–52.
Gomes BC, Kleinman A, Carvalho AF, Pereira TC, Gurgel AP, Lafer B, et al. Quality of life in youth with bipolar disorder and unaffected offspring of parents with bipolar disorder. J Affect Disord. 2016;202:53–7.
Simon GE. Social and economic burden of mood disorders. Biol Psychiatry. 2003;54:208–15.
Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin. 2004;20:139–54.
Kleinman NL, Brook RA, Rajagopalan K, Gardner HH, Brizee TJ, Smeeding JE. Lost time, absence costs, and reduced productivity output for employees with bipolar disorder. J Occup Environ Med. 2005;47:1117–24.
Sierra P, Livianos L, Rojo L. Quality of life for patients with bipolar disorder: relationship with clinical and demographic variables. Bipolar Disord. 2005;7:159–65.
Altshuler LL, Post RM, Black DO, Keck PE Jr, Nolen WA, Frye MA, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry. 2006;67:1551–60.
Samalin L, Tixeront C, Llorca PM. Asénapine dans le trouble bipolaire: efficacité, tolérance et utilisation en pratique clinique [Asenapine in bipolar disorder: efficacy, safety and place in clinical practice]. Encephale. 2012;38:257–65.
Caresano C, Di Sciascio G, Fagiolini A, Maina G, Perugi G, Ripellino C, et al. Cost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context. Adv Ther. 2014;31:873–90.
Detke HC, DelBello MP, Landry J, Usher RW. Olanzapine/fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2015;54:217–24.
Poznanski EO, Mokros HB. Children’s depression rating scale-revised: manual. Los Angeles: Western Psychological Services; 1996.
Symbyax (olanzapine and fluoxetine hydrochloride) US prescribing information. Indianapolis, IN: Eli Lilly and Company, 2015. http://pi.lilly.com/us/symbyax-pi.pdf. Accessed 10 Dec 2015.
Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:213–35.
Pfeifer JC, Kowatch RA, DelBello MP. The use of antipsychotics in children and adolescents with bipolar disorders. Expert Opin Pharmacother. 2007;8:2673–87.
Findling RL, Nyilas M, Forbes RA, McQuad RD, Jin N, Iwamoto T, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70:1441–51.
Rademacher J, DelBello MP, Adler C, Stanford K, Strakowski SM. Health-related quality of life in adolescents with bipolar I disorder. J Child Adolesc Psychopharmacol. 2007;17:97–103.
Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:60–70.
Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164:1547–56.
Olsen BT, Ganocy SJ, Bitter SM, Findling RL, Case M, Chang K, et al. Health-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine. Compr Psychiatry. 2012;53:1000–5.
Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54:1031–7.
Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41:1205–15.
Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S, Fluoxetine Pediatric OCD Study Team, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 2001;40:773–9.
Vitiello B, Rohde P, Silva S, Wells K, Casat C, Waslick B, et al. TADS team: functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006;45:1419–26.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition text revision (DSM-IV-TR). Washington DC: American Psychiatric Association; 2000.
Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980–8.
Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35.
Ravens-Sieberer U, Bullinger M. KINDL: questionnaire for measuring health-related quality of life in children and adolescents. Munich: Ravens-Sieberer & Bullinger; 2000.
Bullinger M, von Mackensen S, Kirchberger I. KINDL-ein Fragebogen zur Erfassung der gesundheitsbezogenen Lebensqualität von Kindern. Zeitschrift für Gesundheitspsychologie. 1994;2:64–77.
Ravens-Sieberer U, Bullinger M. Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results. Qual Life Res. 1998;7:399–407.
Findling RL, Pathak S, Earley WR, Liu S, DelBello MP. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2014;24:325–35.
Emslie GJ, Prakash A, Zhang Q, Pangallo BA, Bangs ME, March JS. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2014;24:170–9.
Mayes TL, Bernstein IH, Haley CL, Kennard BD, Emslie GJ. Psychometric properties of the children’s depression rating scale-revised in adolescents. J Child Adolesc Psychopharmacol. 2010;20:513–6.
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988.
Taylor J, Jacoby A, Baker GA, Marson AG. Self-reported and parent-reported quality of life of children and adolescents with new-onset epilepsy. Epilepsia. 2011;52:1489–98.
Eiser C, Morse R. Can parents rate their child’s health-related quality of life? Results of a systemtic review. Qual Life Res. 2001;10:347–57.
Jozefiak T, Larsson B, Wichstrom L. Changes in quality of life among Norwegian school children: a six-month follow-up study. Health Qual Life Outcomes. 2009;7:7.
Depp CA, Davis CE, Mittal D, Patterson TL, Jeste DV. Health-related quality of life and functioning of middle-aged and elderly adults with bipolar disorder. J Clin Psychiatry. 2006;67:215–21.
Yen CF, Chen CC, Lee Y, Tang TC, Ko CH, Yen JY. Association between quality of life and self-stigma, insight, and adverse effects of medication in patients with depressive disorders. Depress Anxiety. 2009;26:1033–9.
West AE, Celio CI, Henry DB, Pavuluri MN. Child mania rating scale-parent version: a valid measure of symptom change due to pharmacotherapy. J Affect Disord. 2011;128:112–9.
Meyer M, Oberhoffer R, Hock J, Giegerich T, Müller J. Health-related quality of life in children and adolescents: current normative data, determinants and reliability on proxy-report. J Paediatr Child Health. 2016;52:628–31.
Weinstein SM, West AE, Pavuluri M. Psychosocial intervention for pediatric bipolar disorder: current and future directions. Expert Rev Neurother. 2013;13:843–50.
West AE, Weinstein SM, Peters AT, Katz AC, Henry DB, Cruz RA, et al. Child- and family-focused cognitive-behavioral therapy for pediatric bipolar disorder: a randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2014;53:1168–78.
Hlastala SA, Kotler JS, McClellan JM, McCauley EA. Interpersonal and social rhythm therapy for adolescents with bipolar disorder: treatment development and results from an open trial. Depress Anxiety. 2010;27:457–64.
Miklowitz DJ, Axelson DA, Birmaher B, George EL, Taylor DO, Schneck CD, et al. Family-focused treatment for adolescents with bipolar disorder: results of a 2-year randomized trial. J Affect Disord. 2004;82(Suppl 1):S113–28.
Van Meter AR, Henry DB, West AE. What goes up must come down: the burden of bipolar depression in youth. J Affect Disord. 2013;150:1048–54.